Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (GSK2857916; belamaf; BLENREP)

被引：0
|
作者：
Kortuem, M. [1 ]
Terpos, E. [2 ]
Badros, A. [3 ]
Popat, R. [4 ]
Rodriguez-Otero, P. [5 ]
Farooq, A. [6 ]
Jeng, B. [3 ]
Esposti, Degli S. [7 ,8 ]
Lewis, E. [9 ]
Gupta, I [10 ]
Opalinska, J. [10 ]
Palumbo, A. [11 ]
Trudel, S. [12 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[4] Univ Coll London Hosp, NHS Fdn Trust, London, England
[5] Clin Univ Navarra, Inst Invest Sanitaria Navarra, Navarra, Spain
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[8] UCL Inst Ophthalmol, London, England
[9] GlaxoSmithKline, Res Triangle Pk, NC USA
[10] GlaxoSmithKline, Upper Providence, PA USA
[11] GlaxoSmithKline, Zug, Switzerland
[12] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep211
引用
收藏
页码：204 / 204
页数：1
相关论文
共 30 条
  • [1] Relationship Between Corneal Exam Findings, Best-Corrected Visual Acuity (BCVA), and Ocular Symptoms in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Receiving Belantamab Mafodotin (GSK2857916; Belamaf)
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Degli Esposti, Simona
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S421 - S421
  • [2] Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).
    Terpos, Evangelos
    Badros, Ashraf
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim
    Jeng, Bennie
    Esposti, Simona Degli
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin
    Terpos, Evangelos
    Badros, Ashraf Z.
    Popat, Rakesh
    Rodriguez-Otero, Paula
    Farooq, Asim V.
    Jeng, Bennie
    Esposti, Simona Degli
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    Palumbo, Antonio
    Trudel, Suzanne
    Jadhav, Vinay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S160 - S160
  • [4] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Richardson, P. G.
    Trudel, S.
    Callander, N.
    Nooka, A.
    Song, K.
    Uttervall, K.
    Minnema, M. C.
    Rodriguez-Otero, P.
    Struemper, H.
    Yeakey, A.
    de Oca, Montes R.
    Smith, L. M.
    Jackson, N.
    Kaisermann, M.
    Im, E.
    Basile, F. G.
    Ahlers, C. M.
    Holkova, B.
    Gupta, I
    Kremer, B. E.
    Quach, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
  • [5] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [6] DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul G.
    Trudel, Suzanne
    Callander, Natalie S.
    Nooka, Ajay
    Song, Kevin
    Uttervall, Katarina
    Minnema, Monique C.
    Rodriguez-Otero, Paula
    Struemper, Herbert
    Yeakey, Anne
    de Oca, Rocio Montes
    Smith, L. Mary
    Jackson, Nicola
    Kaisermann, Morrys
    Im, Ellie
    Basile, Frank G.
    Ahlers, Christoph M.
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Quach, Hang
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S156 - S156
  • [7] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [8] Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
    Hultcrantz, Malin
    Anderson, Larry D., Jr.
    Anwer, Faiz
    Gasparetto, Cristina
    Kocoglu, Mehmet H.
    Lichtman, Eben I.
    Mo, Clifton
    Niesvizky, Ruben
    Lewis, Eric
    Li, Hong
    Paul, Sofia
    Petrone, Stephanie
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S440
  • [9] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Kortuem, M.
    Lee, H. C.
    Cohen, A. D.
    Chari, A.
    Hultcrantz, M.
    Nooka, A. K.
    Callander, N.
    Suvannasankha, A.
    Badros, A.
    Libby, E.
    Trudel, S.
    Richardson, P.
    Sborov, D.
    Rodriguez Otero, P.
    Lonial, S.
    Zhi, E.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 102 - 102
  • [10] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.
    Lee, Hans Chulhee
    Cohen, Adam D.
    Chari, Ajai
    Hultcrantz, Malin
    Nooka, Ajay K.
    Callander, Natalie Scott
    Suvannasankha, Attaya
    Badros, Ashraf
    Libby, Edward N.
    Trudel, Suzanne
    Richardson, Paul G.
    Sborov, Douglas Weston
    Rodriguez Otero, Paula
    Lonial, Sagar
    Zhi, Eric
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
123